76 related articles for article (PubMed ID: 15322760)
1. Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors.
Jung LL; Ramanathan RK; Egorin MJ; Jin R; Belani CP; Potter DM; Strychor S; Trump DL; Walko C; Fakih M; Zamboni WC
Cancer Chemother Pharmacol; 2004 Dec; 54(6):487-96. PubMed ID: 15322760
[TBL] [Abstract][Full Text] [Related]
2. Clinical and pharmacokinetic study evaluating the effect of food on the disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in patients with solid tumors.
Zamboni WC; Goel S; Iqbal T; Parise RA; Strychor S; Repinski TV; Egorin MJ; Mani S
Cancer Chemother Pharmacol; 2006 May; 57(5):631-9. PubMed ID: 16205924
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumors.
Zamboni WC; Jung LL; Egorin MJ; Potter DM; Friedland DM; Belani CP; Agarwala SS; Wong MM; Fakih M; Trump DL; Jin R; Strychor S; Vozniak M; Troetschel M; Ramanathan RK
Clin Cancer Res; 2004 Aug; 10(15):5058-64. PubMed ID: 15297407
[TBL] [Abstract][Full Text] [Related]
4. Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes.
Zamboni WC; Ramanathan RK; McLeod HL; Mani S; Potter DM; Strychor S; Maruca LJ; King CR; Jung LL; Parise RA; Egorin MJ; Davis TA; Marsh S
Invest New Drugs; 2006 Sep; 24(5):393-401. PubMed ID: 16505951
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of the in vivo and in vitro conversion of 9-nitro-20(S)-camptothecin to 9-amino-20(S)-camptothecin in humans, dogs, and mice.
Hinz HR; Harris NJ; Natelson EA; Giovanella BC
Cancer Res; 1994 Jun; 54(12):3096-100. PubMed ID: 8205523
[TBL] [Abstract][Full Text] [Related]
6. A phase I pharmacokinetics study of 9-nitrocamptothecin in patients with advanced solid tumors.
Yan Z; Zhu Z; Li K; Chen P; Wang L; Huang C; Xue J; Liu M
Cancer Chemother Pharmacol; 2011 Apr; 67(4):955-61. PubMed ID: 21191594
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusion.
Eder JP; Supko JG; Lynch T; Bryant M; Vosburgh E; Shulman LN; Xu G; Kufe DW
Clin Cancer Res; 1998 Feb; 4(2):317-24. PubMed ID: 9516917
[TBL] [Abstract][Full Text] [Related]
8. Tumor, tissue, and plasma pharmacokinetic studies and antitumor response studies of docetaxel in combination with 9-nitrocamptothecin in mice bearing SKOV-3 human ovarian xenografts.
Zamboni WC; Strychor S; Joseph E; Parise RA; Egorin MJ; Eiseman JL
Cancer Chemother Pharmacol; 2008 Aug; 62(3):417-26. PubMed ID: 17957368
[TBL] [Abstract][Full Text] [Related]
9. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
[TBL] [Abstract][Full Text] [Related]
10. A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin).
Gerrits CJ; Schellens JH; Burris H; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Von Hoff DD; Verweij J
Clin Cancer Res; 1999 Jan; 5(1):69-75. PubMed ID: 9918204
[TBL] [Abstract][Full Text] [Related]
11. A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin.
Rubin E; Wood V; Bharti A; Trites D; Lynch C; Hurwitz S; Bartel S; Levy S; Rosowsky A; Toppmeyer D
Clin Cancer Res; 1995 Mar; 1(3):269-76. PubMed ID: 9815982
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacokinetics of encapsulated oral 9-aminocamptothecin in plasma and saliva.
de Jonge MJ; Verweij J; Loos WJ; Dallaire BK; Sparreboom A
Clin Pharmacol Ther; 1999 May; 65(5):491-9. PubMed ID: 10340914
[TBL] [Abstract][Full Text] [Related]
13. Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors.
Gelderblom H; Salazar R; Verweij J; Pentheroudakis G; de Jonge MJ; Devlin M; van Hooije C; Seguy F; Obach R; Pruñonosa J; Principe P; Twelves C
Clin Cancer Res; 2003 Sep; 9(11):4101-7. PubMed ID: 14519632
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacokinetic study of gimatecan given orally once a week for 3 of 4 weeks in patients with advanced solid tumors.
Zhu AX; Ready N; Clark JW; Safran H; Amato A; Salem N; Pace S; He X; Zvereva N; Lynch TJ; Ryan DP; Supko JG
Clin Cancer Res; 2009 Jan; 15(1):374-81. PubMed ID: 19118068
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
16. Relationship between plasma exposure of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite and antitumor response in mice bearing human colon carcinoma xenografts.
Zamboni WC; Jung LL; Egorin MJ; Hamburger DR; Joseph E; Jin R; Strychor S; Ramanathan RK; Eiseman JL
Clin Cancer Res; 2005 Jul; 11(13):4867-74. PubMed ID: 16000585
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies.
Homsi J; Simon GR; Garrett CR; Springett G; De Conti R; Chiappori AA; Munster PN; Burton MK; Stromatt S; Allievi C; Angiuli P; Eisenfeld A; Sullivan DM; Daud AI
Clin Cancer Res; 2007 Oct; 13(19):5855-61. PubMed ID: 17908979
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacological study of a new camptothecin derivative, exatecan mesylate (DX-8951f), infused over 30 minutes every three weeks.
Minami H; Fujii H; Igarashi T; Itoh K; Tamanoi K; Oguma T; Sasaki Y
Clin Cancer Res; 2001 Oct; 7(10):3056-64. PubMed ID: 11595695
[TBL] [Abstract][Full Text] [Related]
19. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly.
Haas NB; LaCreta FP; Walczak J; Hudes GR; Brennan JM; Ozols RF; O'Dwyer PJ
Cancer Res; 1994 Mar; 54(5):1220-6. PubMed ID: 8118810
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and bioavailability of oral 9-aminocamptothecin capsules in adult patients with solid tumors.
Sparreboom A; de Jonge MJ; Punt CJ; Nooter K; Loos WJ; Porro MG; Verweij J
Clin Cancer Res; 1998 Aug; 4(8):1915-9. PubMed ID: 9717819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
